艾昆纬-监测新冠肺炎对欧盟4国和英国医药市场的影响（英）-2023-67页

Analysis and Summary of COVID-19 Impact on Pharmaceutical Market in EU4 & UK (Q2 2023)

Long COVID Impact

The report highlights Long COVID as a significant issue, with widespread symptoms such as fatigue, shortness of breath, and neuropsychiatric manifestations. Prevalence is highest in females aged 35-69 years in the UK, affecting over 1.9 million people. Key challenges include lack of medical recognition, insufficient healthcare support, and barriers to evidence-based treatment. Rehabilitation and multidisciplinary approaches are recommended, but gaps remain in care. Patient advocacy groups are driving R&D and policy changes for Long COVID treatment.

COVID-19 Variants of Concern

SARS-CoV-2 variants, classified by WHO into Variants Under Monitoring (VUM), Variants of Interest (VOI), and Variants of Concern (VOC), continue to evolve. The report details variants like Omicron sublineages (e.g., XBB.1.5), which dominate markets. Variants like BQ.1 and BQ.1.1 show increased vaccine resistance, impacting public health strategies and booster effectiveness. Tracking and monitoring are critical for preparedness.

Vaccination Efforts

Vaccination coverage in EU4 and UK is high, with booster doses prioritizing vulnerable populations. Countries like the UK and Germany are advancing booster campaigns, while the US and Australia simplify bivalent vaccine use. Global approvals for pediatric vaccines and new therapies indicate ongoing innovation, but challenges in accessibility and distribution persist, especially in low-income countries.

Medicine Demand and Supply

Drug demand shows mixed trends: prescription markets in Italy, Germany, and Spain grew due to demand for antiparasitic and respiratory products, while consumer health markets declined in some regions. Supply challenges include fluctuating demand post-COVID, with SHPs (Healthcare Professionals) adapting through remote consultations. Digital supply chains improved, though new variants may pressure healthcare systems.

Engagement with Health Care Professionals

There is a shift to remote interactions, driven by lockdowns during COVID-19. F2F detailing and meetings decreased but stabilized in 2022-2023. The UK and Germany show strong remote engagement, while other countries maintain hybrid models. Patient-centered approaches and telehealth are increasing rehabilitation support and access to care.

Data Sources and Methodology

Data is sourced from secondary research (e.g., WHO, ECDC) and IQVIA sales data (prescription, consumer health). Market analysis uses units growth metrics from 2021 to 2023 for trends, with ATC classification for product categories. Methodology ensures comparability across regions but relies on external data accuracy.

This summary captures key impacts, challenges, and trends based on the provided report.